Veeva：2025年生物制药行业客户参与未来展望白皮书（英文版）

The past three decades have seen a rapid rise in specialty drugs. Thirty years ago, roughly 10 were on the U.S. market; today, there are 671 FDA-approved biologics.1 In 2023, the European Medicines Agency recommended 77 drugs for marketing authorization, including 39 new active substances and 17 orphan drugs supporting treatments for rare diseases.2 The growth gives new hope to healthcare professionals (HCPs) and their patients who lack viable treatment options. But progress doesn’t come with